Cargando…
The pharmacokinetics of oral trazpiroben (TAK‐906) after organic anion transporting polypeptide 1B1/1B3 inhibition: A phase I, randomized study
Trazpiroben is a dopamine D(2)/D(3) receptor antagonist under development for the treatment of gastroparesis. This phase I, open‐label, randomized, two‐way crossover study (NCT04121078) evaluated the effect of single‐dose intravenous rifampin, a potent inhibitor of the organic anion transporting pol...
Autores principales: | Mukker, Jatinder K., Dukes, George, Tolkoff, Max, Wang, Lisi, Almansa, Cristina, Huh, Susanna Y., Nishihara, Mitsuhiro, Ramsden, Diane, Chen, Chunlin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199876/ https://www.ncbi.nlm.nih.gov/pubmed/35460165 http://dx.doi.org/10.1111/cts.13274 |
Ejemplares similares
-
Evaluation of the pharmacokinetics of trazpiroben (TAK‐906) in the presence and absence of the proton pump inhibitor esomeprazole
por: Kaur Mukker, Jatinder, et al.
Publicado: (2022) -
Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D(2)/D(3) Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor
por: Chen, Chunlin, et al.
Publicado: (2021) -
Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D(2)/D(3) Selective Receptor Antagonist for the Management of Gastroparesis
por: Kreckler, Laura, et al.
Publicado: (2022) -
Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK‐906), a Novel Selective D(2)/D(3) Receptor Antagonist: A Phase 1 Randomized, Placebo‐Controlled Single‐ and Multiple‐Dose Escalation Study in Healthy Participants
por: Whiting, Roger L., et al.
Publicado: (2021) -
Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide
por: Jeong, Hyeon-Uk, et al.
Publicado: (2015)